5-Amino-1MQ: What the Evidence Shows, and What FDA Has Said

5-amino-1MQ is not a peptide. It is a small synthetic molecule that blocks an enzyme called NNMT, and everything known about what it does comes from cells and mice. In obese mice it caused modest weight and fat loss without changing how much they ate, and in old mice it helped injured muscle recover.^[1][8] No one has published a study of it in people, and no human trial is registered.^[11] It is not an approved drug, it is on none of FDA’s compounding lists, and in January 2026 FDA cited an outsourcing facility for compounding with it.^[12]

What 5-amino-1MQ is, and why it is not a peptide

The full name is 5-amino-1-methylquinolinium. Peptides are built from strings of amino acids; 5-amino-1MQ is a single ring-shaped molecule from a chemical family called quinoliniums, which researchers at the University of Texas Medical Branch screened in 2017 as blockers of the enzyme nicotinamide N-methyltransferase (NNMT).^[2] The 2018 paper that made it famous calls it a small molecule throughout.^[1] It gets sold beside peptides because it turns up on the same menus and from the same suppliers, not because of what it is.

That difference matters in practice. Peptides are usually injected because the gut digests them. A small molecule can, in principle, be absorbed as a pill, which is why 5-amino-1MQ is often sold as capsules. Whether that works in people has never been measured, and in mice the answer was not encouraging (see below).

What NNMT does, and the link to NAD+

NNMT takes nicotinamide, a form of vitamin B3, and attaches a methyl group to it, using a molecule called SAM as the donor. Nicotinamide is also a raw material the body recycles into NAD+, a coenzyme central to energy metabolism.^[3] So NNMT sits at a fork: the more nicotinamide it methylates, the less is available for the NAD+ recycling pathway.

The idea that blocking it could help with obesity came from a 2014 Harvard study in Nature. NNMT levels were raised in the fat and liver of obese and diabetic mice, and switching the gene down in those tissues protected mice from diet-induced obesity by raising their energy use.^[3] That study used a genetic tool, not a drug. 5-amino-1MQ was the attempt to get the same effect from a compound: in fat cells grown in the lab it lowered NNMT’s product, raised NAD+ and SAM, and reduced fat production.^[1]

This is why 5-amino-1MQ is often marketed next to NAD+ products. The two ideas are related on paper, but neither has human outcome data for the way it is sold. Our review of NAD+ injections covers that side of the story.

Every key 5-amino-1MQ study, and what was actually tested

Does 5-amino-1MQ cause weight loss?

In mice, somewhat. The 2018 study took mice made obese on a high-fat diet and injected them under the skin three times a day for 11 days. Treated mice lost about 2 grams, roughly 5.1% of their weight, while untreated mice gained about 1.4%. Their white fat shrank by about 35%, and they ate about the same amount of food as the controls, which suggests the effect came from changed metabolism rather than appetite.^[1] The researchers saw no obvious harm, but that observation covered nine mice for under two weeks.

Later studies from the same group refined the picture. Paired with a switch to a lower-fat diet, the compound produced about ten times more fat loss than the diet switch alone and brought the mice’s body composition and liver fat back toward that of lean mice.^[4][5] In a 2024 study where the mice stayed on their fattening diet, the higher dose did not cause weight loss; it limited weight gain, to 0.9 grams against 5.4 grams in untreated mice, and improved blood sugar handling and fatty liver.^[6]

Those results are consistent, but they come with caveats a buyer should weigh. The studies are small, run in one mouse strain, and last weeks rather than months. All of them come from one research group, and from 2021 on, the papers disclose that the senior author founded Ridgeline Therapeutics, a company developing NNMT inhibitors, and that co-authors work for it.^[4][6] That does not make the findings wrong, but no independent lab has repeated them in a published study we could find.

Aging muscle: the other half of the story

The second line of research is about muscle. In 24-month-old mice, roughly the equivalent of old age, a leg muscle was injured with a chemical and the mice were injected with 5-amino-1MQ twice a day. Their muscle stem cells were more active, the regrown fibers were nearly twice as large, and the muscle’s peak force was about 70% higher than in untreated mice.^[8] A 2024 follow-up gave old mice the compound daily for eight weeks: grip strength rose about 40% without exercise, against 20% for exercise alone, and about 60% when the two were combined.^[9]

That is the basis for claims that 5-amino-1MQ preserves muscle, which is appealing to people losing weight on a GLP-1. But the studies were in old, sedentary or injured mice, not in people losing weight, and none measured muscle during weight loss in humans. What has actually been measured in people on GLP-1s is covered in muscle volume versus muscle function on a GLP-1.

Capsules versus injections: the route problem

Every mouse study that showed an effect injected the compound under the skin. Many products sold to consumers are capsules. The only published oral data are animal measurements, and they disagree: in rats, about 38% of an oral dose reached the bloodstream,^[7] but in mice it was 3.5%, which the researchers attributed to poor absorption from the gut and fast breakdown in the liver.^[6] Nobody has measured how much of a swallowed capsule reaches the blood in a person, so any oral dose on a label is a guess.

Researchers in the field are frank about the gaps. A 2026 review of NNMT inhibitors noted that weak target engagement, poor bioavailability and “unknown safety profiles” have limited the earlier compounds, and described newer molecules designed to fix those problems.^[10]

Side effects and safety: what is known

Almost nothing, for people. The mouse studies reported no visible adverse effects over days to weeks, and in old mice a blood chemistry panel looked normal.^[1][8] There are no published toxicity studies in people and no human side-effect profile.

One finding deserves attention. When the developers screened 5-amino-1MQ against a broad panel of receptors and enzymes, it showed little off-target activity except one: it blocked 67.4% of the activity of monoamine oxidase-A (MAO-A) at the concentration tested.^[6] MAO-A breaks down serotonin and other signaling chemicals, and drugs that block it are known for interactions with certain antidepressants and foods. Whether 5-amino-1MQ blocks MAO-A meaningfully in a person has never been tested. The authors themselves suggested part of its effect on blood sugar might come through MAO-A rather than NNMT.^[6] Anyone taking an antidepressant or other medicine should raise this with a prescriber before using it.

How it compares with approved GLP-1 drugs

The gap is not just in the size of the effect but in the kind of evidence. Semaglutide and tirzepatide were tested for more than a year in thousands of people against placebo, with side effects counted.^[19][20] 5-amino-1MQ has a handful of short studies in mice. Many compounds that work in obese mice never work in people. How GLP-1 results build over time is in semaglutide results by week and tirzepatide week by week.

Is 5-amino-1MQ legal? FDA status in October 2026

A US pharmacy compounding under section 503A may use an ingredient only if it has an official monograph, is part of an FDA-approved drug, or is on FDA’s 503A bulks list.^[13] 5-amino-1MQ meets none of the three. It does not appear on FDA’s list of nominated 503A substances, including the Category 1 group that FDA lets pharmacies use while it reviews them,^[14] and FDA has said it will not place substances nominated from January 2025 onward into those categories.^[13] It is also absent from the 503B nomination list for outsourcing facilities.^[15]

FDA has already acted on that point. In a warning letter dated January 20, 2026, the agency told GenoGenix, a Florida outsourcing facility, that it had compounded drugs with substances not eligible under 503B:^[12]

“Your facility compounded drug products using bulk drug substances that are not eligible for the use in compounding under section 503B, including 5-amino-1-methylquinolinium iodide (5-Amino-1MQ) and nicotinamide adenine dinucleotide (NAD+).”^[12]

— FDA warning letter to GenoGenix LLC, January 20, 2026

FDA added that the company’s response did not document what happened to its 5-amino-1MQ products or show it had stopped making them.^[12] The full letter is summarized on our GenoGenix warning letter page, and the two compounding channels are explained in 503A vs 503B pharmacies.

Why some suppliers have an NDC number for it

Searching FDA’s National Drug Code database turns up six listings for 5-amino-1MQ, all registered as bulk ingredients rather than finished medicines, by firms in China and India.^[17] A listing means a company filed paperwork with FDA, nothing more. FDA states that inclusion in the directory does not mean it has verified the information or that the product is approved, and that implying approval from an NDC number is misleading.^[16]

The listings also show how loosely the name is used. They list different salts, iodide and chloride, and two of the six give the active ingredient as 5-methylquinoline, a different chemical without the amino group or the charged methyl that define 5-amino-1MQ.^[17] If suppliers’ own filings disagree on what the substance is, a buyer cannot assume a capsule or vial contains what its label says.

“Research use only” 5-amino-1MQ: what the label means

Much of the 5-amino-1MQ sold online carries labels such as “not for human consumption” or “for research use only,” even when it comes as capsules with a daily serving size. FDA’s position, set out in a December 2024 warning letter to a research-peptide seller, is that such a label does not stop a product being an unapproved drug when the seller’s own website shows it is meant for people.^[18] In practice, research-labeled 5-amino-1MQ comes with no prescriber, no pharmacist, no manufacturing standard and no evidence-based dose. The same reasoning applies to research-labeled GLP-1s, covered in buying tirzepatide as a research chemical.

If a clinic offers 5-amino-1MQ as part of a weight-loss plan, ask which pharmacy makes it and under what authority, given that it is on no compounding list, and make sure whoever prescribes your other medicines knows you are taking it. The wider pattern across clinic add-ons is laid out in the peptide menu, sorted by human evidence and are peptides legal.